Navigation Links
New Critical Path Report Highlights Research Needed to Foster,Generic Drug Development

ROCKVILLE, Md., May 2, 2007-The U.S. Food and Drug Administration (FDA) today issued the "Critical Path Opportunities for Generic Drugs" report identifying many of the unanswered scientific questions that impede the development of generic versions of commonly used drugs.

The report is part of FDA's Critical Path Initiative, established in 2004 to discern what challenges exist in moving a promising drug, biologic or device along the critical path from discovery, or proof of concept, to a marketable product. Solving these challenges will require the expertise and input of many groups, including scientists from universities, patient groups, government, industry, associations and other private organizations.

"This report pinpoints the barriers that are limiting the availability of additional generic drug options," said Gary Buehler, R.Ph., director, FDA's Office of Generic Drugs. "We hope these findings will encourage research collaboration, lower these barriers and accelerate access to safe and effective generic drugs."

Before they can be approved, generic drugs must have the same active ingredient, dosage form, strength, and conditions of use as the brand name drug. The drugs must also be absorbed at the same rate and in the same amount, a concept known as bioequivalence.

While straightforward tests of blood plasma levels are sufficient to demonstrate bioequivalence for most generic drug candidates, these common tests generally are not appropriate for certain drugs, including asthma inhalers, nasal sprays, and topical skin applications such as anti-fungal creams. As a result, few generic versions are available in these product categories, resulting in less competition and higher prices.

For example, generic drug products that contain the ozone-depleting substance chlorofluorocarbon will be withdrawn from the market after 2008. The new report will help ensure FDA has an adequate scientific basis to review inhaler applications that use an alternative, hydrofluoroalkane.

The report also calls for research on new bioequivalence methods tailor-made for each challenging drug class. These include lung function tests and molecular level imaging for inhalation drugs; particle size distribution tests for nasal sprays; and methods for direct measurement of drug delivered to the skin.

In addition, the report highlights possible research projects that might lead to new modeling and simulation tools for drug absorption, drug release and other drug development issues and to alternative methods for seeking waivers from clinical bioequivalence studies.

Last year FDA issued the Critical Path Opportunities Report listing 76 specific scientific projects that, if undertaken, would help modernize the Critical Path sciences. This companion document focuses more narrowly on the scientific challenges unique to the development of generic drugs.

To learn more about the Critical Path Initiative consult:
www.fda.gov/oc/initiatives/criticalpath/

Information on FDA's Generic Drug Office is available at:
www.fda.gov/cder/ogd/index.htm.

####

Media Inquiries:
Karen Riley, 301-827-6242
Consumer Inquiries:
888-INFO-FDA


'"/>




Related medicine technology :

1. NIEHS Researchers Identify Enzyme Critical in DNA Replication
2. Velcade (bortezomib) for Injection Based Induction Therapy Delivered High Post-Transplant Complete Remission Rate, a Critical Marker for Increased Overall Survival
3. Critical Therapeutics Announces the Publication of Data for ZyfloCR (Zileuton) Extended-Release Tablets in the Journal of Asthma
4. Critical Therapeutics Announces the Publication of New Preclincial HMGB1 Data in Nature Immunology
5. Data Show SuperGens Multi-Targeted Tyrosine Kinase Inhibitor Suppresses Critical Double-Stranded DNA Repair Protein, Rad51
6. MIV Therapeutics Announces Pivotal Test Results Further Validating Company Stent Coatings Meet Critical FDA Fatigue Guidelines
7. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
8. Gene Therapy Eradicates Pancreatic Cancer in Preclinical Trial Targeting Systems Success in Mouse Model Reported in Cancer Cell
9. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
10. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
11. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... , Feb. 8, 2016 In a historic vote among its ... to construct a medical cannabis cultivation facility and dispensary on tribal land ... New York as a provider for patients in the state,s ... as a provider for patients in the state,s Medical Cannabis ... (34) to approve the project and pursue designation from the ...
(Date:2/8/2016)...   Intarcia Therapeutics, Inc. today announced the ... the newly created role of Vice President, Head of ... two decades of leadership experience at leading pharmaceutical, biotechnology, ... medical center. Most recently Dr. Yee served as VP, ... Head Medical Officer at AstraZeneca, where he led medical ...
(Date:2/8/2016)... PAOLI, Pa. , Feb. 8, 2016  As part ... Ltd has announced today the appointment of Lori Chmura ... more than 20 years in the industry, Chmura,s extensive experience ... in the advancement of Dune Medical Devices. ... Lori will be responsible for leading all sales, marketing and ...
Breaking Medicine Technology:
(Date:2/8/2016)... ... February 08, 2016 , ... ... newly redesigned website, federallabs.org . The site houses a wealth of federal ... federal technologies through the process called technology transfer (T2). As a network of ...
(Date:2/8/2016)... ... , ... The Valentine’s Season is famous for gift giving with flowers, chocolates and other tokens ... This year, for more than 5.6 million Americans suffering with Alzheimer’s, those store bought ... remind them of the lives they’ve led and the people they’ve touched. , ...
(Date:2/8/2016)... ... February 08, 2016 , ... Tingley Rubber Corporation ... to provide its range of unique and advantaged protective solutions to a ... will provide bilingual customer service and marketing support. A new distribution center in ...
(Date:2/8/2016)... ... February 08, 2016 , ... Delta Dental of California and its affiliated companies ... Gary D. Radine, who recently retired as president and CEO of Delta Dental of ... CEO of the Year , helped lead the effort to raise funds for studies ...
(Date:2/8/2016)... ... February 08, 2016 , ... FileHold's document management software ... provides a cloud hosted environment for FileHold software that is pay per user ... party applications using the FileHold web services API. DocuSyst also advises clients on ...
Breaking Medicine News(10 mins):